 |
Top 10 Heart disease treatment startups
Updated: April 20, 2024 |
Cardiology startups develop new heart diagnostics, treatment and regeneration
technologies, like genome analysis, AI-powered diagnostics, stem cells, ECG apps and gadgets, new drugs, implantable pulse generators, heart prothesis...
1
Country: USA | Funding: $3.5B
We are developing tools and platforms to enable more continuous health data collection for timely decision-making and effective interventions. We are running longitudinal studies to better understand ways to predict and prevent disease onset and progression. And, we are undertaking significant joint efforts with partners to radically transform the way healthcare is delivered.
We are developing tools and platforms to enable more continuous health data collection for timely decision-making and effective interventions. We are running longitudinal studies to better understand ways to predict and prevent disease onset and progression. And, we are undertaking significant joint efforts with partners to radically transform the way healthcare is delivered.
2
Country: USA | Funding: $1.2B
Cytokinetics develops first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised.
Cytokinetics develops first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised.
3
Country: Netherlands | Funding: $611M
Founded is a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases
Founded is a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases
4
Country: USA | Funding: $419.3M
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary.
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary.
5
Country: USA | Funding: $390.6M
CVRx developed an implantable technology, called Barostim neo, for the treatment of high blood pressure and heart failure.
CVRx developed an implantable technology, called Barostim neo, for the treatment of high blood pressure and heart failure.
6
Country: USA | Funding: $368.4M
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
7
Country: USA | Funding: $337.3M
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
8
Country: Canada | Funding: $292.6M
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
9
Country: USA | Funding: $282.8M
Orchestra BioMed is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. The main focus is on developing new therapies for cardiovascular diseases
Orchestra BioMed is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. The main focus is on developing new therapies for cardiovascular diseases
10
Country: USA | Funding: $280.5M
Cleerly is a digital healthcare company that provides diagnostic solutions for people with heart disease.
Cleerly is a digital healthcare company that provides diagnostic solutions for people with heart disease.
11
Country: France | Funding: $232.6M
The mission of every team member at Carmat is to contribute to the development of innovative artificial organs – the artificial heart today, tomorrow other vital organs – to treat millions of patients affected by advanced disease of these organs and to restore their normal life.
The mission of every team member at Carmat is to contribute to the development of innovative artificial organs – the artificial heart today, tomorrow other vital organs – to treat millions of patients affected by advanced disease of these organs and to restore their normal life.
12
Country: Canada | Funding: $225M
BlueRock Therapeutics is pioneering cell therapies that replace dead, damaged, or dysfunctional cells to restore critical natural functions in the body. The company is initially targeting severe brain and heart conditions, two areas of critical unmet medical need with blockbuster potential.
BlueRock Therapeutics is pioneering cell therapies that replace dead, damaged, or dysfunctional cells to restore critical natural functions in the body. The company is initially targeting severe brain and heart conditions, two areas of critical unmet medical need with blockbuster potential.
13
Country: USA | Funding: $167M
Rivus Pharmaceuticals is dedicated to improving metabolic health by developing controlled metabolic accelerators (CMAs) that treat metabolic disorders, including the tricky nonalcoholic steatohepatitis (NASH), cardio-metabolic diseases and obesity, via weight loss.
Rivus Pharmaceuticals is dedicated to improving metabolic health by developing controlled metabolic accelerators (CMAs) that treat metabolic disorders, including the tricky nonalcoholic steatohepatitis (NASH), cardio-metabolic diseases and obesity, via weight loss.
14
Country: USA | Funding: $154.3M
AliveCor is a leading FDA-cleared mobile heart solution that helps save lives, save money, and bring healthcare into the 21st century.
AliveCor is a leading FDA-cleared mobile heart solution that helps save lives, save money, and bring healthcare into the 21st century.
15
Country: USA | Funding: $145M
Bitterroot is harnessing the power of immunotherapy to develop and deliver transformative medicines for patients with cardiovascular disease
Bitterroot is harnessing the power of immunotherapy to develop and deliver transformative medicines for patients with cardiovascular disease
16
Country: USA | Funding: $138.2M
Cutting-edge technology that empowers employees to improve heart health.
Cutting-edge technology that empowers employees to improve heart health.
17
Country: USA | Funding: $129.7M
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
18
Country: USA | Funding: $128.2M
Eko creates FDA approved software, AI, and heart sound and EKG sensors for heart disease monitoring.
Eko creates FDA approved software, AI, and heart sound and EKG sensors for heart disease monitoring.
19
Country: USA | Funding: $115M
resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. esTORbio’s lead program has demonstrated in several clinical trials, including a randomized, placebo-controlled trial, the potential to treat multiple diseases of aging for which there are no approved therapies.
resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. esTORbio’s lead program has demonstrated in several clinical trials, including a randomized, placebo-controlled trial, the potential to treat multiple diseases of aging for which there are no approved therapies.
20
Country: USA | Funding: $98M
MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure
MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure
21
Country: USA | Funding: $96.2M
CircuLite is a cardiovascular device company, focused on developing minimally-invasive micro-pumps to treat chronic heart failures.
CircuLite is a cardiovascular device company, focused on developing minimally-invasive micro-pumps to treat chronic heart failures.
22
Country: USA | Funding: $39.4M
SynCardia Systems is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart.
SynCardia Systems is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart.
23
Country: Japan | Funding: $86.3M
Heartseed is a biotech company developing iPSC-derived highly purified ventricular cardiomyocytes for heart failure
Heartseed is a biotech company developing iPSC-derived highly purified ventricular cardiomyocytes for heart failure
24
Country: Germany | Funding: €80M
Cardior Pharmaceuticals discovers and develops medicines and therapeutics for the treatment and prevention of heart disease.
Cardior Pharmaceuticals discovers and develops medicines and therapeutics for the treatment and prevention of heart disease.
25
Country: China | Funding: $78.5M
VoxelCloud provides automated medical image analysis services and diagnosis assistance based on AI and cloud computing technologies. VoxelCloud develops computer-aided detection systems for detecting and diagnosing various diseases ranging from cardiovascular and lung diseases to eye diseases. Our solutions are based on the state-of-the-art computer vision, deep learning and artificial intelligence technology.
VoxelCloud provides automated medical image analysis services and diagnosis assistance based on AI and cloud computing technologies. VoxelCloud develops computer-aided detection systems for detecting and diagnosing various diseases ranging from cardiovascular and lung diseases to eye diseases. Our solutions are based on the state-of-the-art computer vision, deep learning and artificial intelligence technology.
26
Country: USA | Funding: $77.9M
Incarda Therapeutics offers a novel approach to treat cardiovascular conditions and diseases by the inhalation route.
Incarda Therapeutics offers a novel approach to treat cardiovascular conditions and diseases by the inhalation route.
27
Country: Israel | Funding: $74M
Magenta Medical has developed a temporary venous catheter-based therapy for hospital-admitted patients with Acute Decompensated Heart Failure (ADHF).
Magenta Medical has developed a temporary venous catheter-based therapy for hospital-admitted patients with Acute Decompensated Heart Failure (ADHF).
28
Country: France | Funding: $73.6
Volta Medical has developed an AI-enabled software for interventional cardiac electrophysiology
Volta Medical has developed an AI-enabled software for interventional cardiac electrophysiology
29
Country: USA | Funding: $67M
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
30
Country: UK | Funding: $58.9M
Ultromics clinicians and engineers working together to set new standards for world-class cardiovascular diagnostic tools.
Ultromics clinicians and engineers working together to set new standards for world-class cardiovascular diagnostic tools.
31
Country: USA | Funding: $56.3M
Heart Health Intelligence creates heart data collecting toilet seat, reducing the cost of heart failure through seamless in-home monitoring.
Heart Health Intelligence creates heart data collecting toilet seat, reducing the cost of heart failure through seamless in-home monitoring.
32
Country: Ireland | Funding: $54M
LUMA Vision develops a 4D imaging and navigation end-to-end platform for cardiac applications, focusing on point-of-therapy data delivery.
LUMA Vision develops a 4D imaging and navigation end-to-end platform for cardiac applications, focusing on point-of-therapy data delivery.
33
Country: South Korea | Funding: $42M
Sky Labs is developing a smart ring-like device called CART (Cardio Tracker) that is capable of diagnoising and managing atrial fibrillation (AF) — a form of heart disease that results in irregular heartbeat rhythms.
Sky Labs is developing a smart ring-like device called CART (Cardio Tracker) that is capable of diagnoising and managing atrial fibrillation (AF) — a form of heart disease that results in irregular heartbeat rhythms.
34
Country: USA | Funding: $40M
BiVACOR is a privately held company founded in 2008. Our staff includes world-class engineers, medical specialists, and business executives, who are diligently working to advance this ground-breaking technology. Together, we have established a strong collaborative network that extends both nationally and internationally. Our world headquarters is located in Houston, Texas, USA, and our international office is in Brisbane, Australia.
BiVACOR is a privately held company founded in 2008. Our staff includes world-class engineers, medical specialists, and business executives, who are diligently working to advance this ground-breaking technology. Together, we have established a strong collaborative network that extends both nationally and internationally. Our world headquarters is located in Houston, Texas, USA, and our international office is in Brisbane, Australia.
35
Country: USA | Funding: $39.6M
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease.
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease.
36
Country: Ireland | Funding: $36.6M
Neuro Tronik develops a medical device as an alternative for the drugs used currently to treat heart failures.
Neuro Tronik develops a medical device as an alternative for the drugs used currently to treat heart failures.
37
Country: Germany | Funding: $37.3M
OMEICOS Therapeutics is developing a novell molecule utilizing a new Mode of Action for the treatment and prevention of atrial fibrillation.
OMEICOS Therapeutics is developing a novell molecule utilizing a new Mode of Action for the treatment and prevention of atrial fibrillation.
38
Country: USA | Funding: $35.5M
Bardy Diagnostics created a new, state-of-the-art heart monitor known as Carnation Ambulatory Monitor that can be worn comfortably and discreetly for up to 7 days. Unlike many other heart monitors, CAM™ can be worn during exercise or while showering. Its unique, narrow, hourglass shape makes it especially advantageous for the female anatomy.
Bardy Diagnostics created a new, state-of-the-art heart monitor known as Carnation Ambulatory Monitor that can be worn comfortably and discreetly for up to 7 days. Unlike many other heart monitors, CAM™ can be worn during exercise or while showering. Its unique, narrow, hourglass shape makes it especially advantageous for the female anatomy.
39
Country: USA | Funding: $31.6M
Moving Analytics is a provider of turnkey and home-based post-acute care management solutions for cardiopulmonary disease.
Moving Analytics is a provider of turnkey and home-based post-acute care management solutions for cardiopulmonary disease.
40
Country: USA | Funding: $28.5M
Heartbeat is an experience created to screen, diagnose, track and manage cardiovascular risk and disease to keep you at your healthiest.
Heartbeat is an experience created to screen, diagnose, track and manage cardiovascular risk and disease to keep you at your healthiest.
41
Country: France | Funding: $27.5M
Implicity developed a universal remote monitoring platform for cardiac patients with connected pacemakers and implantable defibrillators.
Implicity developed a universal remote monitoring platform for cardiac patients with connected pacemakers and implantable defibrillators.
42
Country: Singapore | Funding: $23.5M
Tricog develops cloud-connected ECG systems to help doctors detect heart complications within minutes of a patient’s arrival.
Tricog develops cloud-connected ECG systems to help doctors detect heart complications within minutes of a patient’s arrival.
43
Country: France | Funding: €22M
To treat Aortic Stenosis, Cardiawave has developed a non-invasive, real-time image-guided medical device using a cutting-edge ultrasound technology, known as Pulsed Cavitational Ultrasound Therapy (PCUT).
To treat Aortic Stenosis, Cardiawave has developed a non-invasive, real-time image-guided medical device using a cutting-edge ultrasound technology, known as Pulsed Cavitational Ultrasound Therapy (PCUT).
44
Country: Singapore | Funding: $23.5M
Tricog Health offers AI-based cardiac diagnostic tools to help solve cardiovascular conditions by identifying them in real-time and with accuracy.
Tricog Health offers AI-based cardiac diagnostic tools to help solve cardiovascular conditions by identifying them in real-time and with accuracy.
45
Country: France | Funding: $23.1M
By applying the latest research in Artificial intelligence, Cardiologs provides a web solution to streamline this process at large scale, enabling the highest diagnostic yield, for the least physician effort.
By applying the latest research in Artificial intelligence, Cardiologs provides a web solution to streamline this process at large scale, enabling the highest diagnostic yield, for the least physician effort.
46
Country: Israel | Funding: $20M
Sensible Medical develops accurate, absolute, actionable lung fluid measurement system for heart failure patients
Sensible Medical develops accurate, absolute, actionable lung fluid measurement system for heart failure patients
47
Country: USA | Funding: $17.5M
Underdog develops easy-to-use drugs that prevent common age-related conditions such as atherosclerosis, heart-attack and stroke by addressing the root cause - a build-up of arterial plaque.
Underdog develops easy-to-use drugs that prevent common age-related conditions such as atherosclerosis, heart-attack and stroke by addressing the root cause - a build-up of arterial plaque.
48
Country: USA | Funding: $10.7M
AUM Cardiovascular’s vision is to reduce needless death due to coronary artery disease. Diagnose obstructive coronary artery disease in patients presenting with chest pain and two or more risk factors.
AUM Cardiovascular’s vision is to reduce needless death due to coronary artery disease. Diagnose obstructive coronary artery disease in patients presenting with chest pain and two or more risk factors.
49
Country: Finland | Funding: $15.2M
CardioSignal offers a digital cardiac biomarker for self-monitoring, remote care, and point-of-care diagnostics.
CardioSignal offers a digital cardiac biomarker for self-monitoring, remote care, and point-of-care diagnostics.
50
Country: USA | Funding: $14.1M
Murj dedicated to helping clinicians streamline care for patients with implantable cardiac devices. Murj greets the challenge of managing the rapid growth of cardiac device data as an opportunity to improve care and deliver insight. Murj aims to liberate device clinics from paper reports and inadequate management tools, freeing clinicians to get back to the heart of the matter – their patients.
Murj dedicated to helping clinicians streamline care for patients with implantable cardiac devices. Murj greets the challenge of managing the rapid growth of cardiac device data as an opportunity to improve care and deliver insight. Murj aims to liberate device clinics from paper reports and inadequate management tools, freeing clinicians to get back to the heart of the matter – their patients.